|
1
|
O’Sullivan J, Whyte L, Drake J and
Tenniswood M: Alterations in the post-translational modification
and intracellular trafficking of clusterin in MCF-7 cells during
apoptosis. Cell Death Differ. 10:914–927. 2003.PubMed/NCBI
|
|
2
|
Shannan B, Seifert M, Leskov K, et al:
Challenge and promise: roles for clusterin in pathogenesis,
progression and therapy of cancer. Cell Death Differ. 13:12–19.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tenniswood MP, Guenette RS, Lakins J,
Mooibroek M, Wong P and Welsh JE: Active cell death in
hormone-dependent tissues. Cancer Metastasis Rev. 11:197–220. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Redondo M, Villar E, Torres-Munoz J,
Tellez T, Morell M and Petito CK: Overexpression of clusterin in
human breast carcinoma. Am J Pathol. 157:393–399. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miyake H, Gleave M, Kamidono S and Hara I:
Overexpression of clusterin in transitional cell carcinoma of the
bladder is related to disease progression and recurrence. Urology.
59:150–154. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xie D, Lau SH, Sham JS, et al:
Up-regulated expression of cytoplasmic clusterin in human ovarian
carcinoma. Cancer. 103:277–283. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kang YK, Hong SW, Lee H and Kim WH:
Overexpression of clusterin in human hepatocellular carcinoma. Hum
Pathol. 35:1340–1346. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miyake H, Hara S, Arakawa S, Kamidono S
and Hara I: Overexpression of clusterin is an independent
prognostic factor for nonpapillary renal cell carcinoma. J Urol.
167:703–706. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Leskov KS, Klokov DY, Li J, Kinsella TJ
and Boothman DA: Synthesis and functional analyses of nuclear
clusterin, a cell death protein. J Biol Chem. 278:11590–11600.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moretti RM, Marelli MM, Mai S, et al:
Clusterin isoforms differentially affect growth and motility of
prostate cells: possible implications in prostate tumorigenesis.
Cancer Res. 67:10325–10333. 2007. View Article : Google Scholar
|
|
11
|
Tenniswood M, Flanagan L, Whyte L and
Chatterjee N: Effects of clusterin over-expression on metastatic
progression and therapy in breast cancer. BMC Cancer. 10:1072010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu AJ, Park II, Zhaung L and Lee C:
Response to a lethal dose of heat shock by a transient
up-regulation of clusterin expression followed by down-regulation
and apoptosis in prostate and bladder cancer cells. Prostate.
53:277–285. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sensibar JA, Sutkowski DM, Raffo A, et al:
Prevention of cell death induced by tumor necrosis factor alpha in
LNCaP cells by overexpression of sulfated glycoprotein-2
(clusterin). Cancer Res. 55:2431–2437. 1995.PubMed/NCBI
|
|
14
|
Miyake H, Nelson C, Rennie PS and Gleave
ME: Testosterone-repressed prostate message-2 is an antiapoptotic
gene involved in progression to androgen independence in prostate
cancer. Cancer Res. 60:170–176. 2000.PubMed/NCBI
|
|
15
|
Scaltriti M, Santamaria A, Paciucci R and
Bettuzzi S: Intracellular clusterin induces G2-M phase arrest and
cell death in PC-3 prostate cancer cells1. Cancer Res.
64:6174–6182. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Faivre S, Kroemer G and Raymond E: Current
development of mTOR inhibitors as anticancer agents. Nat Rev Drug
Discov. 5:671–688. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Engelman JA: Targeting PI3K signalling in
cancer: opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Downward J: Targeting RAS and PI3K in lung
cancer. Nat Med. 14:1315–1316. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gustafson AM, Soldi R, Anderlind C, et al:
Airway PI3K pathway activation is an early and reversible event in
lung cancer development. Sci Transl Med. 2:26ra252010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luo J, Manning BD and Cantley LC:
Targeting the PI3K-Akt pathway in human cancer: rationale and
promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J, Zhang N, Li B, et al: Decline of
serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable
predictive factor for tumor response. Tumour Biol. 32:689–695.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Resnicoff M, Ambrose D, Coppola D and
Rubin R: Insulin-like growth factor-1 and its receptor mediate the
autocrine proliferation of human ovarian carcinoma cell lines. Lab
Invest. 69:756–760. 1993.PubMed/NCBI
|
|
23
|
Schneider MR, Lahm H, Wu M, Hoeflich A and
Wolf E: Transgenic mouse models for studying the functions of
insulin-like growth factor-binding proteins. FASEB J. 14:629–640.
2000.PubMed/NCBI
|
|
24
|
LeRoith D, Werner H, Beitner-Johnson D and
Roberts CT Jr: Molecular and cellular aspects of the insulin-like
growth factor I receptor. Endocr Rev. 16:143–163. 1995. View Article : Google Scholar
|
|
25
|
Saltiel AR and Kahn CR: Insulin signalling
and the regulation of glucose and lipid metabolism. Nature.
414:799–806. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Myers MG Jr, Sun XJ, Cheatham B, et al:
IRS-1 is a common element in insulin and insulin-like growth
factor-I signaling to the phosphatidylinositol 3′-kinase.
Endocrinology. 132:1421–1430. 1993.
|
|
27
|
Adams TE, Epa VC, Garrett TP and Ward CW:
Structure and function of the type 1 insulin-like growth factor
receptor. Cell Mol Life Sci. 57:1050–1093. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Baserga R, Peruzzi F and Reiss K: The
IGF-1 receptor in cancer biology. International journal of cancer.
Int J Cancer. 107:873–877. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gualberto A and Pollak M: Emerging role of
insulin-like growth factor receptor inhibitors in oncology: early
clinical trial results and future directions. Oncogene.
28:3009–3021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ulanet DB, Ludwig DL, Kahn CR and Hanahan
D: Insulin receptor functionally enhances multistage tumor
progression and conveys intrinsic resistance to IGF-1R targeted
therapy. Proc Natl Acad Sci USA. 107:10791–10798. 2010. View Article : Google Scholar
|
|
31
|
Ko JC, Hong JH, Wang LH, et al: Role of
repair protein Rad51 in regulating the response to gefitinib in
human non-small cell lung cancer cells. Mol Cancer Ther.
7:3632–3641. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gridelli C, Rossi A and Maione P:
Treatment of non-small-cell lung cancer: state of the art and
development of new biologic agents. Oncogene. 22:6629–6638. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pallis AG, Serfass L, Dziadziusko R, et
al: Targeted therapies in the treatment of advanced/metastatic
NSCLC. Eur J Cancer. 45:2473–2487. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carney DN: Lung cancer--time to move on
from chemotherapy. N Engl J Med. 346:126–128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baserga R: The IGF-I receptor in cancer
research. Exp Cell Res. 253:1–6. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Petropoulou C, Trougakos IP, Kolettas E,
Toussaint O and Gonos ES: Clusterin/apolipoprotein J is a novel
biomarker of cellular senescence that does not affect the
proliferative capacity of human diploid fibroblasts. FEBS Lett.
509:287–297. 2001. View Article : Google Scholar
|
|
37
|
Stahel RA and Zangemeister-Wittke U:
Antisense oligonucleotides for cancer therapy-an overview. Lung
Cancer. 41(Suppl 1): S81–S888. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Suzuki CM, Goetz E, Veneziano G, et al:
Secretory clusterin (sCLU) is a hallmark sensor of DNA damage, cell
stress, and cellular senescence: Evidence for similar regulation of
sCLU expression after cellular stress and replicative senescence.
ICS. 1299:150–157. 2007.
|
|
39
|
Zellweger T, Miyake H, July LV, Akbari M,
Kiyama S and Gleave ME: Chemosensitization of human renal cell
cancer using antisense oligonucleotides targeting the antiapoptotic
gene clusterin. Neoplasia. 3:360–367. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jo H, Jia Y, Subramanian KK, Hattori H and
Luo HR: Cancer cell-derived clusterin modulates the
phosphatidylinositol 3′-kinase-Akt pathway through attenuation of
insulin-like growth factor 1 during serum deprivation. Mol Cell
Biol. 28:4285–4299. 2008.PubMed/NCBI
|
|
41
|
Goetz EM, Shankar B, Zou Y, et al:
ATM-dependent IGF-1 induction regulates secretory clusterin
expression after DNA damage and in genetic instability. Oncogene.
30:3745–3754. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ammar H and Closset JL: Clusterin
activates survival through the phosphatidylinositol 3-kinase/Akt
pathway. J Biol Chem. 283:12851–12861. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rychahou PG, Jackson LN, Silva SR,
Rajaraman S and Evers BM: Targeted molecular therapy of the PI3K
pathway: therapeutic significance of PI3K subunit targeting in
colorectal carcinoma. Ann Surg. 243:833–842; discussion 843–834.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pitt SC, Chen H and Kunnimalaiyaan M:
Inhibition of phosphatidylinositol 3-kinase/Akt signaling
suppresses tumor cell proliferation and neuroendocrine marker
expression in GI carcinoid tumors. Ann Surg Oncol. 16:2936–2942.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li C, Liu VW, Chan DW, Yao KM and Ngan HY:
LY294002 and metformin cooperatively enhance the inhibition of
growth and the induction of apoptosis of ovarian cancer cells. Int
J Gynecol Cancer. 22:15–22. 2012. View Article : Google Scholar : PubMed/NCBI
|
